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Abstract
In order to assess the effect of a health care intervention, it is useful to look
at an ensemble of relevant studies. The Cochrane Collaboration’s admirable
goal is to provide systematic reviews of all relevant clinical studies, in order to
establish whether or not there is a conclusive evidence about a specific interven-
tion. This is done mainly by conducting a meta-analysis: a statistical synthesis
of results from a series of systematically collected studies. Health practition-
ers often interpret a significant meta-analysis summary effect as a statement
that the treatment effect is consistent across a series of studies. However, the
meta-analysis significance may be driven by an effect in only one of the studies.
Indeed, in an analysis of two domains of Cochrane reviews we show that in a
non-negligible fraction of reviews, the removal of a single study from the meta-
analysis of primary endpoints makes the conclusion non-significant. Therefore,
reporting the evidence towards replicability of the effect across studies in addi-
tion to the significant meta-analysis summary effect will provide credibility to
the interpretation that the effect was replicated across studies. We suggest an
objective, easily computed quantity, we term the r-value, that quantifies the
extent of this reliance on single studies. We suggest adding the r-values to the
main results and to the forest plots of systematic reviews.
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1 Introduction
In systematic reviews, several studies that examine the same questions are analyzed
together. Viewing all the information is extremely valuable for practitioners in the
health sciences. A notable example is the Cochrane systematic reviews on the effects
of healthcare interventions. The process of preparing and maintaining Cochrane
systematic reviews is described in detail in their manual [Higgins et al., 2011]. The
reviews attempt to assemble all the evidence that is relevant to a specific healthcare
intervention.
Deriving conclusions about the overall health benefits or harms from an ensemble
of studies can be difficult, since the studies are never exactly the same and there
is danger that these differences affect the inference. For example, factors that are
particular to the study, such as the specific cohorts in the study that are from specific
populations exposed to specific environments, the specific experimental protocol used
in the study, the specific care givers in the study, etc., may have an impact on the
treatment effect.
A desired property of a systematic review is that the effect has been observed in
more than one study, i.e., the overall conclusion is not entirely driven by a single
study. If a significant meta-analysis finding becomes non-significant by leaving out
one of the studies, this is worrisome for two reasons: first, the finding may be too
particular to the single study (e.g., the specific age group in the study); second, there
is greater danger that the significant meta-analysis finding is due to bias in the single
study (e.g., due to improper randomization or blindness). We view this problem as a
replicability problem: the conclusion about the significance of the effect is completely
driven by a single study, and thus we cannot rule out the possibility that the effect
is particular to the single study, i.e., that the effect was not replicated across studies.
A replicability claim is not merely a vague description. A precise computation of the
extent of replicability is possible. An objective way to quantify the evidence that the
meta-analytic findings do not rely on single studies is as follows. For a meta-analysis of
several studies (N studies), the minimal replicability claim is that results have been
replicated in at least two studies. This claim can be asserted if the meta-analysis
results remains significant after dropping (leaving-out) any single study. We suggest
accompanying the review with a quantity we term the r-value, which quantifies the
evidence towards replicability of the effects across studies. The r-value is the largest
of these N meta-analysis p-values. Like a p-value, which quantifies the evidence
against the null hypothesis of no effect, the r-value quantifies the evidence against
no replicability of effects. The smaller the r-value, the greater the evidence that the
conclusion about a primary outcome is not driven by a single study.
The report of the r-value is valuable for meta-analyses of narrow scope as well as of
broad scope. In Section 5.6 of the manual [Higgins et al., 2011] the scope of the review
question is addressed. If the scope is broad, then a review that produced a single meta-
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analytic conclusion may be criticized for ‘mixing apples and oranges’, particularly
when good biologic or sociological evidence suggests that various formulations of
an intervention behave very differently or that various definitions of the condition
of interest are associated with markedly different effects of the intervention. The
advantage of a broad scope is that it can give a comprehensive summary of evidence.
The narrow scope is more manageable, but the evidence may be sparse, and findings
may not be generalizable to other settings or populations. If the r-value is large
(say above 0.05) for a meta-analyses with a narrow scope, this is worrisome since
the scope has already been selected, and the large r-value indicates that an even
stricter selection that removes one single additional study can change the significant
conclusion. If the r-value is large for a meta-analyses with a broad scope, this is
worrisome since the reason for the significant finding may be the single “orange”
among the several (null) “apples”.
We examined the extent of the replicability problem in systematic reviews. We found
that there may be lack of replicability in a large proportion of studies. In Section 2,
we show that out of the 21 reviews with a significant meta-analysis result on the most
important outcomes of interest published on breast cancer, 13 reviews were sensitive
to leaving one study out of the meta-analysis. The problem was less pronounced
in the reviews published on influenza, where 2 reviews were sensitive to leaving one
study out of the meta-analysis, out of 6 updated reviews with significant primary
outcomes.
[Anzures-Carbera and Higgins, 2010] write that a useful sensitivity analysis is one
in which the meta-analysis is repeated, each time omitting one of the studies. A
plot of the results of these meta-analysis, called an ‘exclusion sensitivity plot’ by
[Bax et al, 2006], will reveal any studies that have a particularly large influence on the
results of the meta-analysis. In this work, we concur with this view, but recommend
the most relevant single number of summary information of such a sensitivity analysis
be added to the report of the main results, and to the forest plot, of the meta-analysis.
The code for the computation of the r-values and sensitivity intervals is available from
the first author upon request.
2 The lack of replicability in systematic reviews
We took all the updated reviews in two domains: breast cancer and influenza. Our
eligibility criteria were as follows: (a) the review included forest plots; (b) at least
one primary outcome was reported as significant at the .05 level, which is the default
significant level used in Cochrane Reviews; (c) the meta-analysis of at least one of
the primary outcomes was based on at least three studies and (d) there was no
reporting in the review of unreliable/biased primary outcomes or poor quality of
available evidence. We consider as primary outcomes the outcomes that were defined
as primary by the review authors, and if none were defined we selected the most
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important findings from the review summaries and treated the outcomes for these
findings as primary. We limit ourselves to meta-analyses that include at least three
studies , since this is the minimum number of studies for which even if the single
studies are not significant the meta-analysis may still be non-sensitive (i.e., that a
meta analysis based on every subset of two studies can have a significant finding).
In Cochrane reviews, the meta-analyses are of two types: fixed effect and random
effects. Under the fixed effect model all studies in the meta-analysis are assumed to
share a common (unknown) effect θ. Since all studies share the same effect, it follows
that the observed effect varies from one study to the next only because of the random
error inherent in each study. The summary effect is the estimate of this common effect
θ. Under the random effects model the effects in the studies, θi , i = 1, 2, ..., N , are
assumed to have been sampled from a distribution with mean θ˜. Therefore, there are
two sources of variance: the within-study error in estimating the effect in each study
and the variance in the true effects across studies. The summary effect is the estimate
of the effects distribution mean θ˜. For details on estimation of these effects and their
confidence intervals, see [Higgins et al., 2011]. In this Section our results are based on
the computations of the meta-analysis p-values as suggested in [Higgins et al., 2011],
for both fixed and random effects meta-analyses.
In the breast cancer domain 48 updated reviews were published by the Cochrane
Breast Cancer Group in the Cochrane library, out of which we analyzed 21 updated
reviews that met our eligibility criteria (14, 8 , 4 and 1 reviews was excluded due
reasons a, b, c and d respectively). Out of the 21 eligible reviews, 13 reviews were
sensitive to leaving one study out in at least one primary outcome. Moreover, in 8
out of 13 reviews all the significant primary outcomes were sensitive. The prevalence
of sensitive meta-analyses was similar among the fixed effect and random effect meta-
analyses, see Table 1. Among the 15 fixed effect meta-analyses, 6 reviews where
sensitive in all their primary outcomes, 2 reviews were sensitive in 66% of the primary
outcomes, 1 review was sensitive in 50% of the primary outcomes, and 6 reviews
were not sensitive in any of their primary outcomes. Among the 7 Random effect
meta-analyses, 3 reviews were sensitive in all their primary outcomes, 2 review were
sensitive in 50% of their primary outcomes, and 2 reviews were not sensitive in any
of their primary outcomes.
In the influenza domain 25 reviews were published by different groups (e.g., Cochrane
Acute Respiratory Infections Group, Cochrane Childhood Cancer Group etc.) in the
Cochrane library, out of which we analyzed 6 updated reviews that met our eligibility
criteria (9, 2 , 7 and 1 review was excluded due reasons a, b, c and d respectively).
Our results are summarized in Table 2. Out of the 6 eligible reviews, 2 reviews were
sensitive to leaving 1 study out. Among the two fixed effect meta-analyses reviews,
one review was sensitive in all primary outcomes and one review was not sensitive
in all primary outcomes. Among the five reviews with random effect meta-analyses,
1 review was sensitive in 40% of the primary outcomes, and four reviews were not
sensitive in any of their outcomes.
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Table 1: Table of results for the breast cancer domain. The review name (column
2);the type of meta-analysis (column 3); the number of significant primary outcomes
(column 4); the number of outcomes with r-values at most (0.01,0.05,0.1) (columns
5,6,7); the actual r-values of the primary outcomes, arranged in increasing order
(column 8).The smaller the r-value, the stronger the evidence towards replicability.
The rows are arranged by order of increasing sensitivity; the last 8 rows are sensitive
in all primary outcomes.
number of number of outcomes
significant non-sensitive at level
Review Random/Fixed outcomes 0.01 0.05 0.1 r-values
1 CD004421 Fixed 2 2 2 2 (1.300e-10, 1.405e-07)
2 CD003372 Fixed 2 2 2 2 (4.000e-14, 5.368e-05)
3 CD002943 Fixed 2 2 2 2 (9.853e-09, 0.0012)
4 CD006242 Random 2 2 2 2 (2.580e-09, 0.03549)
5 CD000563 Fixed 1 1 1 1 1.28e-11
6 CD008941 Fixed 1 1 1 1 1.025e-04
7 CD005001 Random 1 0 1 1 0.0335
8 CD003370 Fixed 1 0 1 1 0.05341
9 CD003367 Fixed 2 1 1 1 (7.440e-07, 0.18)
10 CD005211 Random 4 1 2 2 (0.0017, 0.0167, 0.1231, 0.178)
11 CD003474 Random 2 1 1 1 (0.0463, 0.253)
12 CD003366 Fixed 3 1 1 1 (3.200e-05, 0.21, 0.38)
13 CD003139 Fixed 3 1 1 1 (0.1053, 0.1852, 0.002)
14 CD006823 Random 1 0 0 1 0.08
15 CD004253 Random 1 0 0 0 0.1028
16 CD005002 Fixed 1 0 0 0 0.15
17 CD008792 Fixed 1 0 0 0 0.24
28 CD007077 Fixed 1 0 0 0 0.3
19 CD002747 Fixed 1 0 0 0 0.9641
20 CD007913 (Random,Fixed) 2 0 0 0 (0.0712,0.0756)
21 CD003142 Fixed 2 0 0 0 (0.1243,0.1827)
The influenza domain has a much smaller number of reviews with significant primary
results than the breast cancer domain. In the influenza domain, most of the reviews
have non-significant endpoints or low quality of evidence.
3 Calculating and reporting the r-value: examples
In this section we shall give examples of sensitive and non-sensitive (fixed and ran-
dom effect) meta-analyses in the breast cancer domain. For examples in the influenza
domain, see Appendix A. For each example, we shall compute the r-value, which is
based on the N leave-one out meta-analysis p-values, as well as the sensitivity inter-
val, which is the union of these N meta-analysis confidence intervals. The detailed
computations are given in Appendix B. We shall show how to incorporate these new
quantities in the Cochrane reviews’ abstract and forest plots .
Our first example is based on a meta-analysis in review CD006242, analyzed by
the authors as a random effect meta-analysis, which is non-sensitive and thus has
a small r-value. The objective of review CD006242 was to assess the efficacy of
therapy with Trastuzumab in women with HER2-positive metastatic breast cancer.
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Table 2: Table of results for the influenza domain. The review name (column 2);the
type of meta-analysis (column 3); the number of significant primary outcomes (column
4); the number of outcomes with r-values at most (0.01,0.05,0.1) (columns 5,6,7); the
actual r-values of the primary outcomes, arranged in increasing order (column 8).The
smaller the r-value, the stronger the evidence towards replicability. The rows are
arranged by order of increasing sensitivity. The value 0.0001∗ indicates that the
r-value was smaller than 0.0001.
number of number of outcomes
significant non-sensitive at level
Review Random/Fixed outcomes 0.01 0.05 0.1 r-values
1 CD001269 (Fixed,Random) 4 4 4 4 (0.0001∗, 0.0001∗,0.0014, 0.0188)
2 CD001169 Random 4 4 4 4 (0.0001∗ ,0.0014 ,0.0016, 0.0025)
3 CD004879 Random 4 4 4 4 (0.0001∗ ,0.0001∗ ,0.0007, 0.006)
4 CD002744 Random 1 1 1 1 0.0009
5 CD008965 Random 5 1 3 3 (0.0001∗, 0.0108, 0.0471 ,0.118, 0.1206)
6 CD005050 Fixed 1 0 0 0 0.9888
Only one of the studies was (barely) significant, and the remaining four studies had
non-significant effects at the .05 significance level. However, when combined in a
meta-analysis the evidence was highly significant, and the review conclusion was
that Trastuzumab improved overall survival in HER2-positive women with metastatic
breast cancer, see the left panel of Figure 1. This is a nice example that shows
how a meta-analysis can increase power. Even after removing the single significant
study (study number 5) there was still a significant effect in the meta-analysis at
the 0.05 level; see the right panel of Figure 1. The r-value is 0.03549 based on the
meta-analysis computations as suggested in [Higgins et al., 2011]. In a recent paper,
[IntHout et al., 2014] suggested an alternative random effect meta-analysis, which
controls the type I error rate more adequately. The r-value is 0.0366 based on the
meta-analysis computations as suggested in [IntHout et al., 2014].
We suggest accompanying the original forest plot with this r-value, see Figure 2. The
significant meta-analytic conclusion can therefore be accompanied by a statement
that the replicability claim is established at the .05 level of significance. This is
a stronger scientific claim than that of the meta-analysis, and it is supported by
the data in this example. In the main results of Review CD006242 the authors
write ”The combined HRs for overall survival and progression-free survival favoured
the trastuzumab-containing regimens (HR 0.82, 95% confidence interval (CI) 0.71
to 0.94, P = 0.004; moderate-quality evidence)”. To this, we suggest adding the
following information “This result was replicated in more than one study (r-value =
0.03549)”.
Our second example, also from the breast cancer domain, is based on a meta-analysis
in review CD008792, that was analyzed by the authors as a fixed effect meta-analysis.
In this example the fixed effect meta-analysis was sensitive. The objective of Review
CD008792 was to assess the effect of combination chemotherapy compared to the
same drugs given sequentially in women with metastatic breast cancer. In the meta-
analysis a significant finding was discovered, see the left panel of Figure 3. However,
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Figure 1: The forest plot in Review CD006242 (Left) and excluding study 5 (Right).
The r-value was 0.03549. The sensitivity interval, [0.685,0.987], is the confidence
interval excluding study 5 (the black diamond in the right panel) with an additional
(very small) left tail. The axis is on the logarithmic scale.
.
note that the different studies seem to have different effects. Nevertheless, the review
conclusion was that the combination arm had a higher risk of progression than the
sequential arm. After removing study number 7, there was no longer a significant
effect in the meta-analysis, see the right panel of Figure 3. The r-value was 0.24.
The replicability claim was not established at the .05 level of significance. This lack
of replicability, quantified by the r-value, cautions practitioners that the significant
meta-analysis finding may depend critically on a single study.
We suggest accompanying the original forest plot with this r-value, see Figure 4. In
the main results of Review CD008792 the authors write ”The combination arm had
a higher risk of progression than the sequential arm (HR 1.16; 95% CI 1.03 to 1.31; P
= 0.01) with no significant heterogeneity”. To this, we suggest adding the following
information “We cannot rule out the possibility that this result is based on a single
study (r-value = 0.24)”.
In the right panels of Figures 1 and 3, the meta-analysis confidence intervals that
would have been computed had we considered only this specific subset of studies is
shown. The sensitivity intervals has an additional tail in the direction favoured by
the data.
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Figure 2: The forest plot in the original Review CD006242 including the r-value,
which was 0.03549. The asterisks indicate which study was excluded for the r-value
computation.
4 Methodological extensions
4.1 A lower bound on the extent of replicability
A review is less sensitive than another review if a larger fraction of studies are excluded
without reversing the significant conclusions. We can calculate the meta-analysis
significance not only after dropping each single study, but also after dropping all
pairs of studies, triplets of studies etc. Each time we calculate the maximum p-value
and stop at the first time it exceeded α. The bigger the number of studies that can
be dropped, the stronger the replicability claim.
For example, the objective of Review CD004421 was to assess the efficacy of therapy
taxane containing chemotherapy regimens as adjuvant treatment of pre- or post-
menopausal women with early breast cancer. The review included 11 studies, out
of which only three studies were significant, and the remaining eight studies had
non-significant effects. When combined in a meta-analysis, the evidence was highly
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Figure 3: The forest plot in Review CD008792 (Left) and excluding study 7 (Right).
The r-value was 0.24. The sensitivity interval, [0.94, 1.356], is the confidence interval
excluding study 7 (the black diamond in the right panel) with an additional (small)
right tail. The axis is on the logarithmic scale.
significant, and the review conclusion was that the use of taxane containing adjuvant
chemotherapy regimens improved the overall survival of women with early breast
cancer, see Figure 5.
In order to reverse the significant conclusion, we need to leave out 6 studies: for
u = 6, the r-value was 0.0281, but for u = 7, the r-value was 0.0628, see Table 3.
Therefore, with 95% confidence, the true number of studies with an effect (in the
same direction) is at least 6. More generally, testing in order at significance level
α , results in a 1-α confidence lower bound on the number of studies with an effect
in a fixed-effect meta-analysis (see [Heller, 2011] for proof). Note that although we
have a lower bound on the number of studies that show an effect, we cannot point
out to which studies these are. This is so since the pooling of evidence in the same
direction in several studies increases the lower bound, even though each study on it’s
own maybe non-significant.
4.2 Accounting for multiplicity
When more than one primary endpoint is examined, the r-value needs to be smaller
in order to establish replicability. This is exactly the same logic as with p-values,
for which we need to lower the significance threshold when faced with multiplicity of
endpoints. Family-wise error rate (FWER) or false discovery rate (FDR) controlling
procedures can be applied to the individual r-values in order to account for the
multiple primary endpoints, see [Benjamini et al, 2009] for details.
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Figure 4: The forest plot in the original Review CD008792 including the r-value,
which was 0.24. The asterisks indicate which study was excluded for the r-value
computation.
For example, in Review CD005211 four endpoints were examined, with the following
r-values: (1) 0.1231; (2) 0.0017; (3) 0.0167; (4) 0.1776. For FWER control over
replicability claims at the 0.05 level, the Bonferroni-adjusted r-values are the number
of endpoints multiplied by the original r-values. Only endpoint (2) is reported as
replicated using Bonferroni at the 0.05 level, since it is the only Bonferroni-adjusted
r-value below 0.05, 4× 0.0017 < 0.05.
For FDR control over replicability claims, we can use the Benjamini-Hochberg (BH)
procedure ([Benjamini and Hochberg, 1995]) on the reported r-values. The BH-adjusted
r-values for a sorted list of M r-values, r(1) ≤ . . . ≤ r(M), are mini≥j Mr(i)i , j =
1, . . . ,M. In Review CD005211, the sorted list is (0.0017, 0.0167, 0.1231, 0.1776) and
the adjusted r-values are (0.0068, 0.0334, 0.1641, 0.1776). Therefore, endoints (2) and
(3), the two endpoints with the smallest p-values in the sorted list, are reported as
replicated using FDR at the 0.05 level, since for both endpoints the BH-adjusted
r-values are below 0.05.
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Figure 5: The forest plot in the original Review CD004421 including the r-value,
which was 2.91e-06. The asterisks indicate which study was excluded for the r-value
computation.
5 Discussion
In this work we suggested enhancing the systematic reviews meta-analyses, for both
fixed effect and random effects model, with a measure that quantifies the strength of
replicability,i.e., the r-value. In the reporting, if the r-value is small we have evidence
that the conclusion is based on more than one study, i.e., that the effect was replicated
across studies. We suggest adding a cautionary note if the r-value is greater than the
significance level (say = 0.05), that states that the conclusion depends critically on a
single study. This does not mean that the conclusion is necessarily reversed, but the
large r-value warrants another examination of the studies in the meta-analysis, and if
the single study upon which the review relies was very well conducted the conclusion
may still be justified despite it being only a single study.
We would like to emphasize that replicability analysis is relevant for both fixed effect
and random effects model meta analysis. In both cases, the meta-analysis can be
significant even though the true summary effect is greater than zero in only one
study out of the N and hence the replicability analysis is needed. Specifically, for the
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Table 3: The r-value excluding u− 1 studies, for u = 2, . . . , 7, in Review CD004421.
This exclusion is in worst-case order, i.e in order of the study that will show the
highest lower bound.
sensitivity interval
u r-value lower bound exclued study
1 2 2.91e-06 0.89 BCIRG 001
2 3 1.64e-04 0.91 BIG 2-98
3 4 2.29e-03 0.94 Taxit 216
4 5 8.32e-03 0.96 NSABP B-28
5 6 2.81e-02 0.99 HeCOG
6 7 6.28e-02 1.01 PACS 01
random effect model in Appendix C we show simulations where N − 1 studies have
effects θi samples for the normal distribution with zero mean, and one study has effect
µn ∈ {0, . . . , 5}. When µn = 0, the fraction of times the null is rejected at the nominal
0.05 level using a t-test with N −1 degrees of freedoms on the sample of N estimated
effect sizes is about 0.05, and using the meta-analysis computations suggested in
[Higgins et al., 2011] the fraction is at most 0.12. However, when µn > 0, the fraction
of times the null is rejected at the nominal 0.05 level using a t-test withN−1 degrees of
freedoms on the sample ofN estimated effect sizes can be as high as 0.15, and using the
meta-analysis computations suggested in [Higgins et al., 2011] the fraction can reach
almost 0.3. We conclude from these simulations that for meta-analysis, it is better to
use the t-test, and that even with this non-liberal test the significant conclusion can
be entirely driven from a single study. Therefore, a replicability analysis is necessary
in order to rule out the possibility that a significant random effect meta-analysis
conclusion is driven by a single study.
In our two domains there were typically 1-4 primary endpoints per review. We briefly
discussed ways to account for the multiplicity of primary endpoints in assessing repli-
cability in Section 4.2. We regard this as an extension since the emphasis, and the new
contribution, of this paper is the introduction of the r-value into the meta-analysis
conclusions.
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A Examples for the influenza domain
Our first example is based on a meta-analysis in review CD001269, analyzed by
the authors as a random effect meta-analysis, which is non-sensitive and thus has
a small r-value. The objective of Review CD001269 was to assess the effects of
vaccines against influenza in healthy adult. Four studies were significant (all favoured
treatment), and the remaining twelve studies had non-significant effects at the .05
significance level (seven favoured the treatment, five favoured the control). When
combined in a meta-analysis the evidence was significant, and the review conclusion
was that the placebo arm had a higher risk of Influenza-like illness than the vaccine
arm, see the left panel of Figure 6. Even after removing each significant study (in
particular the most influential: study number 9) there was still a significant effect in
the meta-analysis at the 0.05 level, see the right panel of Figure 6. The r-value is
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0.0014. The significant meta-analytic conclusion can therefore be accompanied by a
statement that the replicability claim is established at the .05 level of significance.
This is a stronger scientific claim than that of the meta-analysis, and it is supported
by the data in this example.
We suggest accompanying the original forest plot with this r-value, see Figure 7. Note
that although the referred meta-analysis is significant and the replicability claim is
established at the .05 level of significance, in the main results of Review CD001269
the authors write : ”The overall effectiveness of parenteral inactivated vaccine against
influenza-like illness (ILI) is limited, corresponding to a number needed to vaccinate
(NNV) of 40 (95% confidence interval (CI) 26 to 128)”. to this, we suggest adding the
following information: “This result was replicated in more than one study (r-value =
0.0014)”. The replicability claim is relevant even in the presence of a limited effect
size: at least two studies showed that there is a (possibly limited) effect of parenteral
inactivated vaccine against influenza-like illness (ILI) is limited.
Figure 6: The forest plot in Review CD001269 (Left) and excluding study 9 (Right).
The r-value was 0.0014. The sensitivity interval, [0.75,0.96], is the confidence interval
excluding study 9 (the black diamond in the right panel) with an additional (very
small) left tail. The axis is on the logarithmic scale.
Our second example, also from the influenza domain, is based on a meta-analysis
in review CD001269, analyzed by the authors as a random effects meta-analysis.
In this example the random effect meta-analysis was sensitive. The objective of
Review CD008965 was to describe the potential benefits and harms of Neuraminidase
inhibitors for influenza in all age groups. In the meta-analysis a significant finding
was discovered, see the left panel of Figure 8. Note that only one study was significant
and the remaining seven studies were not significant (with large confidence intervals).
After removing study number 1,there was no longer a significant effect in the meta-
analysis, see the right panel of Figure 8. The r-value was 0.1206 based on the random
effect meta-analysis computations as suggested in [Higgins et al., 2011], and 0.0661
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Figure 7: The forest plot in the original Review CD001269 including the r-value,
which was 0.0014. The asterisks indicate which study was excluded for the r-value
computation.
based on the meta-analysis computations as suggested in [IntHout et al., 2014]. The
replicability claim was not established at the .05 level of significance. This lack
of replicability, quantified by the r-value, cautions practitioners that the significant
meta-analysis finding may depend critically on a single study.
We suggest accompanying the original forest plot with this r-value, see Figure 9. In
the main results of Review CD008965 the authors write ”In adults treatment tri-
als, Oseltamivir significantly reduced self reported, investigator-mediated, unverified
pneumonia (RR 0.55, 95% CI 0.33 to 0.9)” ; To this, we suggest adding the following
information: “We cannot rule out the possibility that this result is based on a single
study (r-value = 0.1206)”. Note that the conclusion was not that complication were
reduced, but this was due to lack of diagnostic definitions. The authors conclusion in
this review was that ”treatment trials with oseltamivir do not settle the question of
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whether the complications of influenza (such as pneumonia) are reduced, because of
a lack of diagnostic definitions”.
Figure 8: The forest plot in Review CD008965 (Left) and excluding study 1 (Right).
The r-value was 0.1206. The sensitivity interval, [0.24, 1.13], is the confidence interval
excluding study 1 (the black diamond in the right panel) with an additional (small)
right tail. The axis is on the logarithmic scale.
B Sensitivity analysis computation details
Let pLi1,...,ik and p
R
i1,...,ik
be, respectively, the left- and right- p-values from a meta-
analysis on the subset (i1, . . . , ik) ⊂ {1, . . . , N} of the N studies in the full meta-
analysis, k < N . Let Π(k) denote the set of all possible subsets of size k.
B.1 The r-value computation
For a meta-analysis based on N studies, a replicability claim is a claim that the
conclusion remains significant (e.g., rejection of the null hypothesis of no treatment
effect) using a meta-analysis of each of the
(
N
u−1
)
subsets of N − u+ 1 studies, where
u = 2, . . . , N is a parameter chosen by the investigator. Specifically, for u = 2, a
replicability claim is a claim that the conclusion remains significant using a meta-
analysis of each of the N subsets of N − 1 studies.
The r-value for replicability analysis, where we claim replicability if the conclusion
remains significant using a meta-analysis of each of the
(
N
u−1
)
subsets of N − u + 1
studies is computed as follows. For left- sided alternative, the r-value is
rL = max
(i1,...,iN−u+1)∈Π(N−u+1)
pLi1,...,iN−u+1 .
16
Figure 9: The forest plot in the original Review CD008965 including the r-value,
which was 0.1206. The asterisks indicate which study was excluded for the r-value
computation.
For right- sided alternative, the r-value is
rR = max
(i1,...,iN−u+1)∈Π(N−u+1)
pRi1,...,iN−u+1 .
For two-sided alternavies, the r-value is
r = 2 min(rL, rR).
B.2 Sensitivity analysis for confidence intervals
The sensitivity interval is the union of all the meta-analysis confidence intervals using
the
(
N
u−1
)
subsets of N − u + 1 studies. The upper limit of the (1 − α) sensitivity
interval is the upper limit of the (1 − α) confidence interval from the meta-analysis
on (iL1 , . . . , i
L
N−u+1), where (i
L
1 , . . . , i
L
N−u+1) is the subset that achieves the maximum
p-value for the left-sided r-value computation. Similarly, the lower limit of the (1−α)
sensitivity interval is the lower limit of the (1−α) confidence interval from the meta-
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analysis on (iR1 , . . . , i
R
N−u+1), where (i
R
1 , . . . , i
R
N−u+1) is the subset that achieves the
maximum p-value for the right-sided r-value computation.
The meta-analysis is non-sensitive (at the desired value of u) if and only if the sensitiv-
ity interval does not contain the null hypothesis value. This follows from the following
argument. To see this, note that r ≤ α, if and only if rL ≤ α/2 or rR ≤ α/2. Since
rL ≤ α/2 if and only if the upper limit of all the meta-analysis 1 − α confidence
intervals of subsets of size N − u + 1 is below the null value, and rR ≤ α/2 if and
only if the lower limit of all the meta-analysis 1−α confidence intervals of subsets of
size N − u+ 1 is above the null value, the result follows.
B.3 Leave-one-out sensitivity procedure
For meta-analysis with N studies and significant effect size θ < θ0 ,where θ0 is the
null effect ,e.g., 1 for HR (two- sided alternative):
1) Compute meta-analysis of each of the
(
N
u−1
)
subsets of N − u+ 1 studies.
2) Choose the N −u+ 1 subset of studies that achieves the maximum p-value for the
left-sided r-value computation: (iL1 , . . . , i
L
N−u+1).
3) Compute the two-sided r-value :
r = 2 min(rL, rR).
4) If the r-value≤ 0.05, the replicability is established in at lease u studies. Otherwise,
the replicability is established in at most u−1 studies (for u=2 , r-value > 0.05 means
that the finding is not replicable).
For meta-analysis with N studies and significant effect size θ > θ0 ,where θ0 is the
null effect ,e.g., 1 for HR (two- sided alternative):
1) Compute meta-analysis of each of the
(
N
u−1
)
subsets of N − u+ 1 studies.
2) Choose the N −u+ 1 subset of studies that achieves the maximum p-value for the
right-sided r-value computation: (iR1 , . . . , i
R
N−u+1).
3) Compute the two-sided r-value :
r = 2 min(rL, rR).
4) If the r-value≤ 0.05, the replicability is established in at lease u studies. Otherwise,
the replicability is established in at most u−1 studies (for u=2 , r-value > 0.05 means
that the finding is not replicable).
C Random effects meta analysis simulation
Using the following simulation we demonstrate that a significant random effect meta-
analysis is not equivalent to replicability. Meaning, random effect meta-analysis can
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be significant even though the effect is greater than zero in only one study out of N .
We show that the probability of rejecting the null hypothesis with a single outlying
study can be as high as 6 times the nominal level using the meta-analysis computa-
tions of [Higgins et al., 2011], and as high as 3 times the nominal level using the more
conservative approach of [IntHout et al., 2014].
For N ∈ {3, 5, 7, 9, 20} studies, we sampled N − 1 effects µi, i = 1, .., N − 1 from
the distribution N(0, τ 2), where τ 2 ∈ {0.01, 0.04, 0.09, 0.25, 0.49, 1}. For the Nth
study, the effect was µn ∈ {0, 0.05, 0.1, . . . , 4.5, 5}. For each study i ∈ {1, . . . , N}, we
sampled observed effects θˆi from the normal distribution with mean µi and standard
deviation 0.01. We computed the random effect meta-analysis one-sided p-value us-
ing the computations suggested in [Higgins et al., 2011], i.e., using the z-test on the
average observed effects, as well as using the t-test on the sample of observed effects.
We estimated the probability of rejection the null hypothesis of zero mean based on
104 iterations.
Figures 10 and 11 show the resulting estimated probability of rejecting the null hy-
pothesis. The random effect meta-analysis is significant in more than 5% of the
iterations for all N in values of µN > 0 that are not too large relative to the value of
τ . The larger the value of τ 2, the greater the range of µN > 0 for which the nominal
level of significance is not maintained.
In [Higgins et al., 2011], the normal distribution is used for the random effect meta-
analysis p-value, instead of the t-distribution with N − 1 degrees of freedom which in
our simulation (with equal study weights) results in an exact α = 0.05 level test when
µN = 0. We see that the usage of the z-test instead of the t-test results in a type
I error rate substantially greater than 5% under the null hypothesis (i.e. µN = 0)
and in a higher rejection rate of the null hypothesis for µN > 0 in comparison to the
fraction of rejections using the t-test when there is no replicability.
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Figure 10: The average fraction of rejections at the 0.05 level, using the z-test detailed
in page 74 of [Higgins et al., 2011]: (a) τ 2 = 0.01; (b) τ 2 = 0.04; (c) τ 2 = 0.09; (d)
τ 2 = 0.25; (e) τ 2 = 0.49; (f) τ 2 = 1. The probability of the type I error is above 0.05
for all Ns and τs, ranging from about ≤ 12% for N = 3 and decreasing to 0.055 for
N = 20. The maximum fraction of rejections is 0.26 for N = 3 and τ 2 = 0.01, and
decreases for increasing N and τ . The range of values of µN for which it is above
5% increases with τ 2 and with N . Even if the z-test is acceptable for meta-analysis
when the number of studies is large enough, we still have a problem with lack of
replicability.
20
Figure 11: The average fraction of rejections at the 0.05 level, using the t-test: (a)
τ 2 = 0.01; (b) τ 2 = 0.04; (c) τ 2 = 0.09; (d) τ 2 = 0.25; (e) τ 2 = 0.49; (f) τ 2 = 1.
The probability of the type I error is 0.05 for all Ns and τs. The maximum fraction
of rejections is 0.15 for N = 3 and τ 2 = 0.01, and decreases for increasing N and τ .
The range of values of µN for which it is above 5% increases with τ
2 as well as with
N . Even though the t-test controls the probability of type I error for meta-analysis,
we still have a problem with lack of replicability.
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